Latest Asx Disclosures News

Star Minerals Limited addresses a sharp rise in its share price and trading volume, attributing the movement to pending assay results from recent drilling activities. The company confirms compliance with ASX disclosure rules while preparing to release interpreted data.

Australian Bond Exchange Holdings has responded to ASX queries confirming the material impact of its involvement in the RBA's Project Acacia and acknowledged a director's breach of trading rules during a closed period.

BPH Energy has responded to an ASX price query following unusual trading activity, confirming no undisclosed information exists and pointing to ongoing legal matters involving its investee Advent Energy as context.

Tyro Payments has acknowledged unsolicited acquisition interest but maintains that current offers undervalue the company. The board remains open to discussions that could unlock shareholder value.

Greatland Resources has downgraded its FY26 gold production target and significantly increased capital expenditure forecasts for its Telfer Project, prompting a sharp share price reaction and detailed ASX disclosure.

Trigg Minerals has disclosed a significant acquisition of the Tennessee Mountain tungsten project in Nevada, explaining recent unusual trading activity in its shares. The company confirms compliance with ASX disclosure rules and plans a full announcement before market open on August 7, 2025.

Lowell Resources Fund (ASX – LRT) has announced a 12-month on-market unit buy-back of up to 10% of its units, aiming to boost unitholder returns and capital efficiency without compromising future growth.

Orcoda Limited has clarified the materiality and timing of disclosures related to its ACTA trial and new SaaS contracts, confirming compliance with ASX Listing Rules and explaining the rationale behind its announcements.

Alterity Therapeutics faces ASX scrutiny after mistakenly marking multiple announcements as market sensitive, prompting a review of its disclosure practices. The biotech denies any intent to manipulate its share price despite repeated errors.

Kaiser Reef reports a solid cash boost to $30.7 million driven by strong production from its Henty and A1 gold mines, while clarifying its gold price risk management strategy.

Botanix Pharmaceuticals confirms material sales and prescription growth data, explaining the timing of its ASX disclosures amid share price fluctuations.

Elsight Limited has responded to ASX concerns over a premature media report on its $60 million capital raise, denying any unauthorized disclosures and reaffirming its compliance with continuous disclosure rules.